BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Ordaōs/NonExomics Deal Shines Light on Novel Mini-Proteins

  Ordaōs and NonExomics announced a research pact Wednesday to develop mini-proteins, called miniPROs, for three specific difficult-to-target rare cancers.

  September 29, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  SFJ Says PhaseBio Must Return Rights to Lead Program

  PhaseBio Pharmaceuticals reported its collaboration partner, SFJ Pharmaceuticals Group, informed the company it would need to return the rights to its lead program.

  September 29, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Novo Nordisk Sinks $70M Cash into Ventus’ NLRP3 Inhibitor

  Novo Nordisk struck a licensing deal Thursday with Ventus Therapeutics valued at up to $700 million to develop and commercialize peripherally-restricted NLRP3 inhibitors.

  September 29, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Clinical Catch-Up: NASH, DMD Spaces Continue to Accelerate

  New data from Axcella, PepGen, Dystrogen and Galecto are showing promise in challenging diseases, including NASH, Duchenne muscular dystrophy and myelofibrosis.

  September 29, 2022

   · 

  4 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Idera Bolsters Rare Disease Portfolio with Aceragen Buyout

  Two rare disease companies - Idera Pharmaceuticals and Aceragen - are merging to pursue the common goal of an FDA approval that could come as early as 2024.

  September 29, 2022

   · 

  2 min read

   · 

  Paul Elias
• 

  Drug Development

  Research Roundup: Disarming Overactive Neutrophils in the Lungs and More

  This week, researchers published results from studies on treatments in lung disease, Alzheimer’s and various cancers. Here’s a look at that and more.

  September 29, 2022

   · 

  4 min read

   · 

  Katherine Davis
• 

  Business

  Movers & Shakers: Lyell Immunopharma, Radionetics Oncology, AlivaMab Discovery and More

  Life science companies made adjustments to their leadership teams with multiple appointments for chief commercial officers, chief business officers and more in this week’s Movers & Shakers.

  September 29, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Approves Third-Ever Drug for ALS - Amylyx’s AMX0035 (Updated)

  The biopharma world - and markets - spent Thursday evening reacting after the FDA gave the green light to only its third-ever drug for ALS, Amylyx’s Relyvrio.

  September 29, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  Sanofi/Regeneron’s Duxipent Scores First US Approval for Prurigo Nodularis

  The FDA has approved Regeneron and Sanofi’s Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, making it the first drug approved for this indication.

  September 29, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Does Biogen and Eisai’s Lecanemab Data Validate the Amyloid Hypothesis? (Updated)

  Eisai and Biogen announced positive data from a Phase III trial in Alzheimer’s of its drug lecanemab. Still, questions remain about the drug’s implications for the future of Alzheimer’s treatment.

  September 29, 2022

   · 

  5 min read

   · 

  Mark Terry